Cover Image
Market Research Report

Corneal Endothelial Dystrophy Market Insights, Epidemiology, and Market Forecast - 2030

Published by DelveInsight Business Research LLP Product code 971973
Published Content info 137 Pages
Delivery time: 1-2 business days
Price
Back to Top
Corneal Endothelial Dystrophy Market Insights, Epidemiology, and Market Forecast - 2030
Published: November 19, 2020 Content info: 137 Pages
Description

DelveInsight's 'Corneal Endothelial Dystrophy (CED) - Market Insights, Epidemiology, and Market Forecast-2030' report delivers an in-depth understanding of the Corneal Endothelial Dystrophy (CED), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Corneal Endothelial Dystrophy (CED) market report provides current treatment practices, emerging drugs and their market share of the individual therapies, current and forecasted Corneal Endothelial Dystrophy (CED) symptoms market size from 2017 to 2030 segmented by seven major markets. The report also covers current Corneal Endothelial Dystrophy (CED) symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Corneal Endothelial Dystrophy (CED) Disease Understanding and Treatment Algorithm

Corneal Endothelial Dystrophy (CED) Overview

Corneal dystrophies are a group of rare genetic diseases that affect the cornea, the front part of your eye. There are more than 20 types, each with different symptoms, all-cause a buildup of foreign material in one or more layers of your cornea. Over time, your vision may become cloudy or blurry.

Corneal dystrophies may not cause symptoms (asymptomatic) in some individuals; in others, they may cause significant vision impairment. The age of onset and specific symptoms vary among the different forms of corneal dystrophy. The disorders have some similar characteristics; most forms of corneal dystrophy affect both eyes (bilateral), progress slowly, do not affect other areas of the body, which tend to run in families. Most forms are inherited as autosomal dominant traits; a few are inherited as autosomal recessive traits.

Corneal Endothelial Dystrophy or Fuchs' endothelial dystrophy is a non-inflammatory, sporadic, or autosomal-dominant dystrophy involving the endothelial layer of the cornea. With Fuchs' dystrophy, the cornea begins to swell, causing glare, halo, and reduced visual acuity. The damage to the cornea in Fuchs' endothelial dystrophy can be so severe as to cause corneal blindness. Fuchs endothelial dystrophy (FED) is characterized by an asymmetrical, bilateral, slowly progressive edema of the cornea in elderly patients. When inherited, the transmission is autosomal dominant. The corneal endothelium is a monolayer of cells that acts as the major pump to deturgesce the cornea and ensures clarity.  

Corneal Endothelial Dystrophy (CED) Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnosis available in the Corneal Endothelial Dystrophy (CED) market for the treatment of the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

The DelveInsight Corneal Endothelial Dystrophy (CED) market report gives a thorough understanding of Corneal Endothelial Dystrophy (CED) symptoms by including details such as disease definition, symptoms, causes, physiology, and diagnosis. It also provides Corneal Endothelial Dystrophy (CED) symptoms of treatment algorithms and treatment guidelines for Corneal Endothelial Dystrophy (CED) symptoms in the US, Europe, and Japan.

The clinical diagnosis of the corneal dystrophies is based on the age of onset and the clinical appearance of the cornea on slit-lamp bio-microscopy. When corneal tissue is excised, it should be examined by light microscopy and TEM, as this can establish the precise diagnosis of many corneal dystrophies. The diagnosis of Fuchs' endothelial dystrophy is clinical; however, some diagnostic tests can be helpful. Pachymetry, or measurement of the central corneal thickness, helps follow a patient with Fuchs' dystrophy. Over time one will see increasing corneal thickness as the disease worsens. The corneal thickness also may help with risk/benefit analysis of any other surgery that may be necessary (such as cataract surgery). Endothelial cell counts can also be helpful when counseling patients as to how quickly their dystrophy may progress as well as how safe any other intraocular surgery might be. In even moderate Fuchs' dystrophy, the cell count can be challenging to obtain. Evaluation of the endothelium by specular microscopy can demonstrate classic changes of Fuchs' endothelial dystrophy, including guttata, variation in cell size and shape, and low cell count per unit area.

For several decades, penetrating keratoplasty has been the only definitive treatment option for FECD. However, the development of minimally invasive lamellar endothelial keratoplasty (EK) procedures has provided key benefits such as better and faster visual recovery, a tectonically stronger globe, decreased risk of bleeding and infection, less astigmatism, less corneal denervation, and lower rejection rates. Newer modalities such as Descemetorhexis without endothelial keratoplasty (DWEK), endothelial cell injection, and nonsurgical approaches may offer options for further minimizing surgical risks and intervening before the onset of symptoms.

Corneal Endothelial Dystrophy (CED) Epidemiology

The Corneal Endothelial Dystrophy (CED) symptoms epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The prevalent cases of Corneal Endothelial Dystrophy (CED) are increasing in 7MM during the study period, i.e., 2017-2030.

The disease epidemiology covered in the report provides historical as well as forecasted Corneal Endothelial Dystrophy (CED) symptoms epidemiology segmented as the Total Prevalent cases of Corneal Endothelial Dystrophy (CED), Gender-specific cases of Corneal Endothelial Dystrophy (CED), Age-Specific cases of Corneal Endothelial Dystrophy (CED), and Type-Specific cases of Corneal Endothelial Dystrophy (CED). The report includes the prevalent scenario of Corneal Endothelial Dystrophy (CED) symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country-wise Corneal Endothelial Dystrophy (CED) Epidemiology

The epidemiology segment also provides the Corneal Endothelial Dystrophy (CED) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total prevalent cases of Corneal Endothelial Dystrophy (CED) associated in 7MM countries was 17,046,314 in 2017.

Corneal Endothelial Dystrophy (CED) Drug Chapters

The drug chapter segment of the Corneal Endothelial Dystrophy (CED) report encloses the detailed analysis of Corneal Endothelial Dystrophy (CED) early-stage (Phase-I/II, and II) pipeline drugs, and marketed drugs. It also helps understand the Corneal Endothelial Dystrophy (CED) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Corneal Endothelial Dystrophy (CED) Marketed Drug

RHOPRESSA: Aerie Pharmaceuticals

Rhopressa (netarsudil ophthalmic solution) is a Rho kinase inhibitor that is supplied as a solution for ophthalmic administration. It possesses three different mechanisms of action in a single agent. The drug lowers the resistance to outflow through the trabecular meshwork and also decreases the production of fluid and episcleral venous pressure. Furthermore, Rhopressa also works at the cellular level within the trabecular network with a novel mechanism of action. The mechanism works by decreasing actin-myosin contraction and reducing actin stress fibers and focal adhesions in the trabecular meshwork to improve the outflow of aqueous humor.

Products detail in the report:

Corneal Endothelial Dystrophy (CED) Market Outlook

The Corneal Endothelial Dystrophy (CED) market outlook of the report helps build the detailed comprehension of the historic, current, and forecasted Corneal Endothelial Dystrophy (CED) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers and demand of better technology.

This segment gives a thorough detail of Corneal Endothelial Dystrophy (CED) market trend of each marketed drug and early-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Corneal Endothelial Dystrophy (CED) market in 7MM is expected to grow in the study period 2017-2030.

Medical management of early Fuchs dystrophy consists of topical hypertonic saline drops or ointment to shorten morning edema. Patients may use the ointment at bedtime and/or the drops upon awakening, typically one drop every 5 min for a total of 3-4 drops; however, this treatment does not change the course of the disease. Patients do note stinging with these agents, which reduces acceptance. Also, a hairdryer held 5-10 inches from the cornea may be used to facilitate corneal deturgescence. As the disease progresses, these interventions will no longer be effective. Once patients are symptomatic from their FECD, surgery is the preferred treatment. Surgical management of endothelial dysfunction has undergone a revolution in the past 20 years. The only medical therapy that has been used to treat Fuchs dystrophy is as an adjuvant to surgical intervention.

Rhopressa (netarsudil ophthalmic solution), developed by Aerie Pharmaceuticals, is also a Rho kinase inhibitor that is supplied as a solution for ophthalmic administration. The drug lowers the resistance to outflow through the trabecular meshwork and also decreases the production of fluid and episcleral venous pressure. It is used as an off-label usage for the treatment of FECD and is approved for the treatment of glaucoma.

Key Findings

This section includes a glimpse of the Corneal Endothelial Dystrophy (CED) market in 7MM. The market size of Corneal Endothelial Dystrophy (CED) in the seven major markets was found to be USD 5.75 Million in 2017.

The United States Market Outlook

This section provides the total Corneal Endothelial Dystrophy (CED) market size and market size by therapies in the United States.

The United States accounts for the largest market size of Corneal Endothelial Dystrophy (CED) in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

EU-5 Countries: Market Outlook

The total Corneal Endothelial Dystrophy (CED) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total Corneal Endothelial Dystrophy (CED) market Size and market Size by therapies in Japan are also mentioned.

Corneal Endothelial Dystrophy (CED) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2017-2030. The analysis covers Corneal Endothelial Dystrophy (CED) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Corneal Endothelial Dystrophy (CED) Pipeline Development Activities

The report provides insights into the therapeutic candidate in Phase I/II, and II stage. It also analyses Corneal Endothelial Dystrophy (CED) key players involved in developing targeted therapeutics.

Major players include Trefoil Therapeutics and Kowa Pharmaceuticals.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Corneal Endothelial Dystrophy (CED) emerging therapies.

Reimbursement Scenario in Corneal Endothelial Dystrophy (CED)

Approaching reimbursement proactively can have a positive impact both during the early stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Descemet's stripping endothelial keratoplasty (DSEK) or deep lamellar endothelial keratoplasty (DLEK) are new forms of keratoplasty. The term keratoplasty has always been a general term relating to surgery on the cornea, usually referring to a corneal graft procedure. Many cornea specialists are embracing these new procedures due to a shorter postoperative recovery for the patient when compared to traditional penetrating keratoplasty. The procedure involves a small incision in the cornea through which the surgeon strips away diseased or opacified endothelial corneal cells. Following stripping, harvested endothelium from a donor cornea is placed on the inner surface of the recipient cornea. The patient's compromised cornea clears rapidly once the new endothelium begins to function, and the common postoperative problems of penetrating keratoplasty related to sutures and astigmatism are avoided. DSEK or DLEK are not considered appropriate for all corneal pathologies; rather they are indicated for corneas with endothelial dysfunction.

KOL - Views

To keep up with current market trends, we take KOLs and SME's opinion working in Corneal Endothelial Dystrophy (CED) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or Corneal Endothelial Dystrophy (CED) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Corneal Endothelial Dystrophy (CED) Market by using various Competitive Intelligence tools that includes - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers the descriptive overview of Corneal Endothelial Dystrophy (CED), explaining its causes, signs and symptoms, physiology, and currently available therapies
  • Comprehensive insight has been provided into the Corneal Endothelial Dystrophy (CED) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Corneal Endothelial Dystrophy (CED) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of the Corneal Endothelial Dystrophy (CED) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Corneal Endothelial Dystrophy (CED) market

Report Highlights:

  • In the coming years, Corneal Endothelial Dystrophy (CED) market is set to change due to the rising awareness of the disease, and Favorable Environment for New Anti-infective Modalities; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Corneal Endothelial Dystrophy (CED) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Corneal Endothelial Dystrophy (CED). The launch of emerging therapies will significantly impact the Corneal Endothelial Dystrophy (CED) market
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase I/II, and II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Corneal Endothelial Dystrophy (CED)Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Corneal Endothelial Dystrophy (CED) Pipeline Analysis
  • Corneal Endothelial Dystrophy (CED) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Corneal Endothelial Dystrophy (CED)Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Corneal Endothelial Dystrophy (CED) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Corneal Endothelial Dystrophy (CED)Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions:

Market Insights:

  • What were the Corneal Endothelial Dystrophy (CED) Market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Corneal Endothelial Dystrophy (CED) total market Size as well as market Size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings of the market across 7MM and which country will have the largest Corneal Endothelial Dystrophy (CED) market Size during the forecast period (2017-2030)?
  • At what CAGR, the Corneal Endothelial Dystrophy (CED) market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Corneal Endothelial Dystrophy (CED) market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Corneal Endothelial Dystrophy (CED) market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of the Corneal Endothelial Dystrophy (CED)?
  • What is the historical Corneal Endothelial Dystrophy (CED) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Corneal Endothelial Dystrophy (CED) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan?
  • What will be the growth opportunities in the 7MM for the patient population of Corneal Endothelial Dystrophy (CED)?
  • Out of all 7MM countries, which country would have the largest prevalent population of Corneal Endothelial Dystrophy (CED) during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Corneal Endothelial Dystrophy (CED) along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Corneal Endothelial Dystrophy (CED) in the USA, Europe, and Japan?
  • What are the Corneal Endothelial Dystrophy (CED) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Corneal Endothelial Dystrophy (CED)?
  • How many therapies are developed by each company for the treatment of Corneal Endothelial Dystrophy (CED)?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of Corneal Endothelial Dystrophy (CED)?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Corneal Endothelial Dystrophy (CED) therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Corneal Endothelial Dystrophy (CED) and their status?
  • What are the key designations that have been granted for the emerging therapies for Corneal Endothelial Dystrophy (CED)?
  • What are the global historical and forecasted market of Corneal Endothelial Dystrophy (CED)?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Corneal Endothelial Dystrophy (CED) market
  • To understand the future market competition in the Corneal Endothelial Dystrophy (CED) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Corneal Endothelial Dystrophy (CED) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Corneal Endothelial Dystrophy (CED) market
  • To understand the future market competition in the Corneal Endothelial Dystrophy (CED) market
Table of Contents
Product Code: DIMI1190

Table of Contents

1 Key Insights

2 Executive summary

3 Organizations

4 Epidemiology and Market Methodology

5 Corneal Endothelial Dystrophy (CED): Market Overview at a Glance

  • 5.1 Total Market Share (%) Distribution of Corneal Endothelial Dystrophy (CED) in 2017
  • 5.2 Total Market Share (%) Distribution of Corneal Endothelial Dystrophy (CED) in 2030

6 Corneal Endothelial Dystrophy (CED): Market Overview at a Glance

  • 6.1 Introduction
  • 6.2 Types of Corneal Dystrophies
  • 6.3 Stages of Fuchs endothelial dystrophy
  • 6.4 Causes
  • 6.5 Signs and Symptoms
  • 6.6 Genetics and Inheritance
  • 6.7 Clinical Presentation
  • 6.8 Pathophysiology
  • 6.9 Prognosis
  • 6.1 Diagnosis
    • 6.10.1 Diagnostic criteria
    • 6.10.2 Differential Diagnosis

7 Epidemiology and Patient Population

  • 7.1 Key Findings
  • 7.2 Assumptions and Rationale
  • 7.3 Total cases of Corneal Endothelial Dystrophy (CED) in 7MM
  • 7.4 United States
    • 7.4.1 Total Prevalent cases of Corneal Endothelial Dystrophy (CED) in the United States
    • 7.4.2 Gender-specific cases of Corneal Endothelial Dystrophy (CED) in the United States
    • 7.4.3 Age-specific cases of Corneal Endothelial Dystrophy (CED) in the United States
    • 7.4.4 Type-specific cases of Corneal Endothelial Dystrophy (CED) in the United States
  • 7.5 EU5 Countries
  • 7.6 Germany
    • 7.6.1 Total Prevalent cases of Corneal Endothelial Dystrophy (CED) in Germany
    • 7.6.2 Gender-specific cases of Corneal Endothelial Dystrophy (CED) in Germany
    • 7.6.3 Age-specific cases of Corneal Endothelial Dystrophy (CED) in Germany
    • 7.6.4 Type-specific cases of Corneal Endothelial Dystrophy (CED) in Germany
  • 7.7 France
    • 7.7.1 Total Prevalent cases of Corneal Endothelial Dystrophy (CED) in France
    • 7.7.2 Gender-specific cases of Corneal Endothelial Dystrophy (CED) in France
    • 7.7.3 Age-specific cases of Corneal Endothelial Dystrophy (CED) in France
    • 7.7.4 Type-specific cases of Corneal Endothelial Dystrophy (CED) in France
  • 7.8 Italy
    • 7.8.1 Total Prevalent cases of Corneal Endothelial Dystrophy (CED) in Italy
    • 7.8.2 Gender-specific cases of Corneal Endothelial Dystrophy (CED) in Italy
    • 7.8.3 Age-specific cases of Corneal Endothelial Dystrophy (CED) in Italy
    • 7.8.4 Type-specific cases of Corneal Endothelial Dystrophy (CED) in Italy
  • 7.9 Spain
    • 7.9.1 Total Prevalent cases of Corneal Endothelial Dystrophy (CED) in Spain
    • 7.9.2 Gender-specific cases of Corneal Endothelial Dystrophy (CED) in Spain
    • 7.9.3 Age-specific cases of Corneal Endothelial Dystrophy (CED) in Spain
    • 7.9.4 Type-specific cases of Corneal Endothelial Dystrophy (CED) in Spain
  • 7.10. UK
    • 7.10.1 Total Prevalent cases of Corneal Endothelial Dystrophy (CED) in the United Kingdom
    • 7.10.2 Gender-specific cases of Corneal Endothelial Dystrophy (CED) in the United Kingdom
    • 7.10.3 Age-specific cases of Corneal Endothelial Dystrophy (CED) in the United Kingdom
    • 7.10.4 Type-specific cases of Corneal Endothelial Dystrophy (CED) in the United Kingdom
  • 7.11 Japan
    • 7.11.1 Total Prevalent cases of Corneal Endothelial Dystrophy (CED) in Japan
    • 7.11.2 Gender-specific cases of Corneal Endothelial Dystrophy (CED) in Japan
    • 7.11.3 Age-specific cases of Corneal Endothelial Dystrophy (CED) in Japan
    • 7.11.4 Type-specific cases of Corneal Endothelial Dystrophy (CED) in Japan

8 Treatment of Corneal Endothelial Dystrophy (CED)

9 Unmet Needs

10 Marketed Drugs

  • 10.1 Rhopressa: Aerie Pharmaceuticals
    • 10.1.1 Drug Description
    • 10.1.2 Regulatory Milestones
    • 10.1.3 Other Development Activities
    • 10.1.4 Clinical Development
    • 10.1.5 Safety and Efficacy
    • 10.1.6 Product Profile

11 Emerging Therapies

    • 11.1.1 Key Cross Competition
  • 11.2 Ripasudil Hydrochloride Hydrate: Kowa Pharmaceuticals
    • 11.2.1 Drug Description
    • 11.2.2 Other Development Activities
    • 11.2.3 Clinical Development
    • 11.2.4 Product Profile
  • 11.3 TTHX 1114: Trefoil Therapeutics
    • 11.3.1 Drug Description
    • 11.3.2 Other Development Activities
    • 11.3.3 Clinical Development
    • 11.3.4 Product Profile

12 Corneal Endothelial Dystrophy (CED): 7 Major Market Analysis

  • 12.1 Key Findings
  • 12.2 Market Size of Corneal Endothelial Dystrophy (CED) in 7MM

13 Seven Major Market Outlook

14 United States Market Size

  • 14.1 Total Market Size of Corneal Endothelial Dystrophy (CED) in the United States
  • 14.2 Total Market Size of Corneal Endothelial Dystrophy (CED) by Therapies in the United States
  • 14.3 Germany
    • 14.3.1 Total market size of Corneal Endothelial Dystrophy (CED) in Germany
    • 14.3.2 Total market size of Corneal Endothelial Dystrophy (CED) by Therapies in Germany
  • 14.4 France
    • 14.4.1 Total market size of Corneal Endothelial Dystrophy (CED) in France
    • 14.4.2 Total Market size of Corneal Endothelial Dystrophy (CED) by Therapies in France
  • 14.5 Italy
    • 14.5.1 Total market size of Corneal Endothelial Dystrophy (CED) in Italy
    • 14.5.2 Total Market size of Corneal Endothelial Dystrophy (CED) by Therapies in Italy
  • 14.6 Spain
    • 14.6.1 Total Market Size of Corneal Endothelial Dystrophy (CED) in Spain
    • 14.6.2 Total market size of Corneal Endothelial Dystrophy (CED) by Therapies in Spain
  • 14.7 United Kingdom
    • 14.7.1 Total market size of Corneal Endothelial Dystrophy (CED) in the United Kingdom
    • 14.7.2 Total market size of Corneal Endothelial Dystrophy (CED) by Therapies in the UK
  • 14.8 Japan
    • 14.8.1 Total market size of Corneal Endothelial Dystrophy (CED) in Japan
    • 14.8.2 Total market size of Corneal Endothelial Dystrophy (CED) by Therapies in Japan

15 Market Drivers

16 Market Barriers

17 SWOT Analysis

18 Market Access

19 Case Study

  • 19.1 A case study of a patient with atypical regressive corneal endothelial cysts in long-term confocal follow-up
  • 19.2 A case study of endothelial keratoplasty for posterior polymorphous corneal dystrophy in a 4-month-old infant
  • 19.3 A case study of eventual endothelial failure after initial corneal clearing after a detached endothelial graft in Fuchs dystrophy

20 KOL Views

21 Appendix

  • 21.1 Report Methodology

22 DelveInsight Capabilities

23 Disclaimer

24 About DelveInsight

List of Tables

  • Table 1: Stages of Fuchs Endothelial Dystrophy
  • Table 2: Total cases of Corneal Endothelial Dystrophy (CED) in 7MM (2017-2030)
  • Table 3: Total Prevalent cases of Corneal Endothelial Dystrophy (CED) in the United States (2017-2030)
  • Table 4: Gender-specific cases of Corneal Endothelial Dystrophy (CED) in the US (2017-2030)
  • Table 5: Age-specific cases of Corneal Endothelial Dystrophy (CED) in the US (2017-2030)
  • Table 6: Type-specific cases of Corneal Endothelial Dystrophy (CED) in the US (2017-2030)
  • Table 7: Total Prevalent cases of Corneal Endothelial Dystrophy (CED) in Germany (2017-2030)
  • Table 8: Gender-specific cases of Corneal Endothelial Dystrophy (CED) in Germany (2017-2030)
  • Table 9: Age-specific cases of Corneal Endothelial Dystrophy (CED) in Germany (2017-2030)
  • Table 10: Type-specific cases of Corneal Endothelial Dystrophy (CED) in Germany (2017-2030)
  • Table 11: Total Prevalent cases of Corneal Endothelial Dystrophy (CED) in France (2017-2030)
  • Table 12: Gender-specific cases of Corneal Endothelial Dystrophy (CED) in France (2017-2030)
  • Table 13: Age-specific cases of Corneal Endothelial Dystrophy (CED) in France (2017-2030)
  • Table 14: Type-specific cases of Corneal Endothelial Dystrophy (CED) in France (2017-2030)
  • Table 15: Total Prevalent cases of Corneal Endothelial Dystrophy (CED) in Italy (2017-2030)
  • Table 16: Gender-specific cases of Corneal Endothelial Dystrophy (CED) in Italy (2017-2030)
  • Table 17: Age-specific cases of Corneal Endothelial Dystrophy (CED) in Italy (2017-2030)
  • Table 18: Type-specific cases of Corneal Endothelial Dystrophy (CED) in Italy (2017-2030)
  • Table 19: Total Prevalent cases of Corneal Endothelial Dystrophy (CED) in Spain (2017-2030)
  • Table 20: Gender-specific cases of Corneal Endothelial Dystrophy (CED) in Spain (2017-2030)
  • Table 21: Age-specific cases of Corneal Endothelial Dystrophy (CED) in Spain (2017-2030)
  • Table 22: Type-specific cases of Corneal Endothelial Dystrophy (CED) in Spain (2017-2030)
  • Table 23: Total Prevalent cases of Corneal Endothelial Dystrophy (CED) in the United Kingdom (2017-2030)
  • Table 24: Gender-specific cases of Corneal Endothelial Dystrophy (CED) in the UK (2017-2030)
  • Table 25: Age-specific cases of Corneal Endothelial Dystrophy (CED) in the UK (2017-2030)
  • Table 26: Type-specific cases of Corneal Endothelial Dystrophy (CED) in the UK (2017-2030)
  • Table 27: Total Prevalent cases of Corneal Endothelial Dystrophy (CED) in Japan (2017-2030)
  • Table 28: Gender-specific cases of Corneal Endothelial Dystrophy (CED) in Japan (2017-2030)
  • Table 29: Age-specific cases of Corneal Endothelial Dystrophy (CED) in Japan (2017-2030)
  • Table 30: Type-specific cases of Corneal Endothelial Dystrophy (CED) in Japan (2017-2030)
  • Table 31: Surgical techniques for the management of Fuchs endothelial corneal dystrophy
  • Table 32: Rhopressa, Clinical Trial Description, 2020
  • Table 33: Ripasudil Hydrochloride Hydrate, Clinical Trial Description, 2020
  • Table 34: TTHX 1114, Clinical Trial Description, 2020
  • Table 35: Market Size of Corneal Endothelial Dystrophy (CED) in 7MM in USD Million (2017-2030)
  • Table 36: US Market Size of Corneal Endothelial Dystrophy (CED) in USD Million (2017-2030)
  • Table 37: US Market Size of Corneal Endothelial Dystrophy (CED) in USD Million (2017-2030)
  • Table 38: Market Size of Corneal Endothelial Dystrophy (CED) in Germany, USD Millions (2017-2030)
  • Table 39: Germany Market Size of Corneal Endothelial Dystrophy (CED) in USD Million (2017-2030)
  • Table 40: Market Size of Corneal Endothelial Dystrophy (CED) associated in France, USD Millions (2017-2030)
  • Table 41: France Market Size of Corneal Endothelial Dystrophy (CED) in USD Million (2017-2030)
  • Table 42: Market Size of Corneal Endothelial Dystrophy (CED) in Italy, USD Millions (2017-2030)
  • Table 43: Italy Market Size of Corneal Endothelial Dystrophy (CED) in USD Million (2017-2030)
  • Table 44: Market Size of Corneal Endothelial Dystrophy (CED) in Spain, USD Millions (2017-2030)
  • Table 45: Spain Market Size of Corneal Endothelial Dystrophy (CED) in USD Million (2017-2030)
  • Table 46: Market Size of Corneal Endothelial Dystrophy (CED) in the UK, USD Millions (2017-2030)
  • Table 47: UK Market Size of Corneal Endothelial Dystrophy (CED) in USD Million (2017-2030)
  • Table 48: Market Size of Corneal Endothelial Dystrophy (CED) in Japan, USD Millions (2017-2030)
  • Table 49: Japan Market Size of Corneal Endothelial Dystrophy (CED) in USD Million (2017-2030)

List of Figures

  • Figure 1: Epidemiology and Market Methodology
  • Figure 2: Total cases of Corneal Endothelial Dystrophy (CED) in 7MM (2017-2030)
  • Figure 3: Total Prevalent cases of Corneal Endothelial Dystrophy (CED) in the United States (2017-2030)
  • Figure 4: Gender-specific cases of Corneal Endothelial Dystrophy (CED) in the US (2017-2030)
  • Figure 5: Age-specific cases of Corneal Endothelial Dystrophy (CED) in the US (2017-2030)
  • Figure 6: Type-specific cases of Corneal Endothelial Dystrophy (CED) in the US (2017-2030)
  • Figure 7: Total Prevalent cases of Corneal Endothelial Dystrophy (CED) in Germany (2017-2030)
  • Figure 8: Gender-specific cases of Corneal Endothelial Dystrophy (CED) in Germany (2017-2030)
  • Figure 9: Age-specific cases of Corneal Endothelial Dystrophy (CED) in Germany (2017-2030)
  • Figure 10: Type-specific cases of Corneal Endothelial Dystrophy (CED) in Germany (2017-2030)
  • Figure 11: Total Prevalent cases of Corneal Endothelial Dystrophy (CED) in France (2017-2030)
  • Figure 12: Gender-specific cases of Corneal Endothelial Dystrophy (CED) in France (2017-2030)
  • Figure 13: Age-specific cases of Corneal Endothelial Dystrophy (CED) in France (2017-2030)
  • Figure 14: Type-specific cases of Corneal Endothelial Dystrophy (CED) in France(2017-2030)
  • Figure 15: Total Prevalent cases of Corneal Endothelial Dystrophy (CED) in Italy (2017-2030)
  • Figure 16: Gender-specific cases of Corneal Endothelial Dystrophy (CED) in Italy (2017-2030)
  • Figure 17: Age-specific cases of Corneal Endothelial Dystrophy (CED) in Italy (2017-2030)
  • Figure 18: Type-specific cases of Corneal Endothelial Dystrophy (CED) in Italy (2017-2030)
  • Figure 19: Total Prevalent cases of Corneal Endothelial Dystrophy (CED) in Spain (2017-2030)
  • Figure 20: Gender-specific cases of Corneal Endothelial Dystrophy (CED) in Spain (2017-2030)
  • Figure 21: Age-specific cases of Corneal Endothelial Dystrophy (CED) in Spain (2017-2030)
  • Figure 22: Type-specific cases of Corneal Endothelial Dystrophy (CED) in Spain (2017-2030)
  • Figure 23: Total Prevalent cases of Corneal Endothelial Dystrophy (CED) in the United Kingdom (2017-2030)
  • Figure 24: Gender-specific cases of Corneal Endothelial Dystrophy (CED) in the UK (2017-2030)
  • Figure 25: Age-specific cases of Corneal Endothelial Dystrophy (CED) in the UK (2017-2030)
  • Figure 26: Type-specific cases of Corneal Endothelial Dystrophy (CED) in the UK (2017-2030)
  • Figure 27: Total Prevalent cases of Corneal Endothelial Dystrophy (CED) in Japan (2017-2030)
  • Figure 28: Gender-specific cases of Corneal Endothelial Dystrophy (CED) in Japan (2017-2030)
  • Figure 29: Age-specific cases of Corneal Endothelial Dystrophy (CED) in Japan (2017-2030)
  • Figure 30: Type-specific cases of Corneal Endothelial Dystrophy (CED) in Japan (2017-2030)
  • Figure 31: Unmet Needs
  • Figure 32: Market Size of Corneal Endothelial Dystrophy (CED) in USD Million (2017-2030)
  • Figure 33: Market Size of Corneal Endothelial Dystrophy (CED) in the US, USD Millions (2017-2030)
  • Figure 34: Market Size of Corneal Endothelial Dystrophy (CED) in the US by therapies, USD Millions (2017-2030)
  • Figure 35: Market Size of Corneal Endothelial Dystrophy (CED) in Germany, USD Millions (2017-2030)
  • Figure 36: Market Size of Corneal Endothelial Dystrophy (CED) in Germany by therapies, USD Millions (2017-2030)
  • Figure 37: Market Size of Corneal Endothelial Dystrophy (CED) in France, USD Millions (2017-2030)
  • Figure 38: Market Size of Corneal Endothelial Dystrophy (CED) in France by therapies, USD Millions (2017-2030)
  • Figure 39: Market Size of Corneal Endothelial Dystrophy (CED) in Italy, USD Millions (2017-2030)
  • Figure 40: Market Size of Corneal Endothelial Dystrophy (CED) in Italy by therapies, USD Millions (2017-2030)
  • Figure 41: Market Size of Corneal Endothelial Dystrophy (CED) in Spain, USD Millions (2017-2030)
  • Figure 42: Market Size of Corneal Endothelial Dystrophy (CED) in Spain by therapies, USD Millions (2017-2030)
  • Figure 43: Market Size of Corneal Endothelial Dystrophy (CED) in the UK, USD Millions (2017-2030)
  • Figure 44: Market Size of Corneal Endothelial Dystrophy (CED) in the UK by therapies, USD Millions (2017-2030)
  • Figure 45: Market Size of Corneal Endothelial Dystrophy (CED) in Japan, USD Millions (2017-2030)
  • Figure 46: Market Size of Corneal Endothelial Dystrophy (CED) in Japan by therapies, USD Millions (2017-2030)
  • Figure 47: Market Drivers
  • Figure 48: Market Barriers
Back to Top